Yunkang Group Limited stock analysis
Want to see HK:2325 full AI Analyst Report?
Yunkang Group Limited (2325) Stock Price & Analysis
2325 Stock Chart & Stats
- Day’s Range
- HKD 0.46 - HKD 0.46
- 52-Week Range
- HKD 0.44 - HKD 1.25
- Previous Close
- HKD 0.46
- Volume
- N/A
- Average Volume (3M)
- 252.02K
- Market Cap
- HKD 285.78M
- Enterprise Value
- -HKD 727.76M
- Total Cash (Recent Filing)
- HKD 1.64B
- Total Debt (Recent Filing)
- HKD 688.17M
- Price to Earnings (P/E)
- 3.9
- Beta
- -0.07
- Next Earnings
- Mar 31, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Jul 04, 2024
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation
Sustained positive operating cash flow and sharply higher free cash flow improve the company’s ability to fund operations internally. This provides financial flexibility for investment, debt management, and resilience across the next several quarters, although cash conversion should remain monitored.
Operating Rebound
The 2025 improvement in operating profitability indicates that the business can still generate healthier economics despite its smaller revenue base. If maintained, the rebound could support reinvestment and stabilize earnings, creating a more durable foundation than the losses reported in 2023 and 2024.
Improved Leverage
The reduction in debt relative to equity represents balance-sheet repair and lowers financial pressure compared with the prior year. A sizable equity base also provides a buffer for operations and capital allocation, giving the company greater flexibility while profitability continues to recover.
Bears Say
Persistent Revenue Contraction
Three consecutive years of revenue decline point to a materially smaller business base and weaker underlying growth momentum. Continued contraction can reduce operating leverage, limit reinvestment capacity, and make the 2025 profitability rebound harder to sustain over the medium term.
Unstable Profitability
The sharp swing from strong earlier profits to losses and then marginal profitability shows limited earnings stability. A net margin of roughly 0.5% leaves little buffer against operational setbacks and makes future results more sensitive to changes in revenue and costs.
Weak Shareholder Returns
Although leverage improved from 2024, debt remains meaningfully above 2021–2022 levels and shareholder returns remain extremely weak. Very low return on equity suggests capital is not yet being deployed productively, limiting the quality of the recovery and long-term value creation.
Yunkang Group Limited News
Yunkang Swings to Profit Despite Revenue Drop on Cost Cuts and Efficiency Gains
Yunkang Group Limited ( ($HK:2325) ) has provided an announcement. Yunkang Group Limited, a healthcare diagnostics service provider focused on medical institution alliances, diagnostic outsourcing, and non-medical testing services in
2325 FAQ
What was Yunkang Group Limited’s price range in the past 12 months?
What is Yunkang Group Limited’s market cap?
When is Yunkang Group Limited’s upcoming earnings report date?
How were Yunkang Group Limited’s earnings last quarter?
Is Yunkang Group Limited overvalued?
Does Yunkang Group Limited pay dividends?
What is Yunkang Group Limited’s EPS estimate?
How many shares outstanding does Yunkang Group Limited have?
What happened to Yunkang Group Limited’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Yunkang Group Limited?
What is the TipRanks Smart Score and how is it calculated?
Yunkang Group Limited Stock Smart Score
Company Description
Yunkang Group Limited
Yunkang Group Limited, established in 2008 and headquartered in Guangzhou, People's Republic of China, operates as a comprehensive provider of medical operational services. The company offers a wide range of diagnostic testing solutions to medical institution alliances, which encompass assisting with the setup and enhancement of diagnostic centers, developing standard operating procedures for testing, delivering expert diagnostic consultations and staff training, sourcing necessary equipment, implementing smart Internet of Things technology, and providing logistics support. For diagnostic outsourcing, Yunkang Group conducts diverse tests, including pathology examinations; infectious disease diagnostics for conditions such as hepatitis B, tuberculosis, human papillomavirus, Epstein-Barr virus, rabies, and respiratory pathogens (via nucleic acid testing); genetic and reproductive health screenings; and routine diagnostic assessments for chronic ailments like kidney, blood, autoimmune, and endocrine metabolic diseases. Furthermore, the company caters to financial institutions and insurance firms by offering personalized diagnostic testing, medical report interpretation, and hospital referral services. Yunkang Group's capabilities also extend to information technology, medical logistics, procurement of medical equipment, healthcare technology development, and various project investments. These services are delivered through its network of independent clinical laboratories and integrated on-site diagnostic facilities.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Yong Zhang
- Employees
- 1,064
- Website
- www.yunkanghealth.com
- Address
- CN
Yunkang Group Limited (2325) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 3 | 14 |
| Technical Analysis | 5 | 3 | 2 |
| Moving Averages | 0 | 0 | 12 |











